The promising clinical outcome results from phase 2 trials of lirentelimab, a mAb to Siglec-8 that both depletes eosinophils and inhibits mast cell degranulation125, and dupilumab, a mAb that targets IL-4 receptor alpha reducing tissue eosinophilia and blocking IL-4/IL-13 signaling126, also suggest that targeting multiple pathways may be more effective. Here, IL4 is linked to Increased total eosinophil count.